Cardinal Health stock inched up over 3% in the premarket session as its earnings for the first quarter soared on a gain from the sale of naviHealth assets. The results exceeded analysts’ expectations. The healthcare services operator reaffirmed its earnings guidance for the full year 2019.
Revenue for the Pharmaceutical segment increased 9% on sales growth from Pharmaceutical Distribution and Specialty Solutions customers, partially offset by the divestiture of the company's China distribution business. Revenue for the Medical segment rose 2% driven primarily by new and existing customers.
For more details of the articles can be found at https://news.alphastreet.com/cardinal-health-earnings-q1-2019-cah-stock/
Revenue for the Pharmaceutical segment increased 9% on sales growth from Pharmaceutical Distribution and Specialty Solutions customers, partially offset by the divestiture of the company's China distribution business. Revenue for the Medical segment rose 2% driven primarily by new and existing customers.
For more details of the articles can be found at https://news.alphastreet.com/cardinal-health-earnings-q1-2019-cah-stock/